Show simple item record

dc.contributor.authorUgarte-Gil, M.F.
dc.contributor.authorSilvestre, A.M.R.
dc.contributor.authorPons-Estel, B.A.
dc.date.accessioned2025-10-31T18:44:37Z
dc.date.available2025-10-31T18:44:37Z
dc.date.issued2015
dc.identifier.urihttps://hdl.handle.net/20.500.12805/6132
dc.description.abstractAccess to an optimal treatment is determined by several factors, like availability, pricing/funding, and acceptability. In Latin America (LA), one of the regions with more disparities particularly on healthcare in the world, access is affected by other factors, including socio-demographic factors like poverty, living in rural regions, and/or health coverage. Regarding rheumatoid arthritis (RA), an inadequate access to specialists leads to diagnosis and treatment delays diminishing the probability of remission or control. Unfortunately, in almost every LA country, there are cities with more than 100,000 inhabitants without rheumatologists; furthermore, a primary care reference system is present in only about half the countries. In the public health system, coverage of biologic disease-modifying antirheumatic drugs occurs for less than 10 % of the patients in about half of the countries. Also, as healthcare providers based their funding decisions mainly in direct costs instead of on patient-centered healthcare quality indicators, access to new drugs is more complicated in this region than in high-income countries. More accurate epidemiological data from LA need to be obtained in order to improve the management of patients with rheumatic diseases in general and RA in particular.en_US
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherSpringer London
dc.relation.ispartofurn:issn:0770-3198
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectSDG 10en_US
dc.subjectRheumatoid Arthritis Management and Patient Outcomesen_US
dc.subjectRheumatoid Arthritis Management and Patient Outcomesen_US
dc.titleAccess to an optimal treatment. Current situationen_US
dc.typehttps://purl.org/coar/resource_type/c_dcae04bc
dc.identifier.doihttps://doi.org/10.1007/s10067-015-3018-7
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.03.00
dc.type.otherReview
dc.identifier.journalClinical Rheumatology
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2